`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Wr"
`lyacnrl lpaSvent - Mean
`
`
`Mean No. New Gd+ Lesions (6
`
`months) — Mean No. Baseline
`
`Gd+ Lesions
`
`Koudriavtseva 1997 (Ex. 1119)
`enencing Vestens
`Na. of
`/
`MeanNo-New.
`|-Mean No.
`
`Gd+-hesions-(6
`i
`Baseline Gd+
`
`Lesions
`Tronths)
`
`Group
`
`0 Lesions on
`Baseline Exam
`
`1 Lesions on
`Baseline Exam
`
`2 Lesions on
`Baseline Exam
`
`3 Lesions on
`Baseline Exam
`
`I
`
`1.9
`
`1.9
`
`3.1
`
`1-0=1
`
`1.9-1=0.9
`
`1.9-2=-0.1
`
`§.1+3=2,]
`
`
`
`1
`
`?
`
`3
`
`
`
`
`
`
`
`
`
`
`
`
`
`Group
`
`
`
`
`
`Mean No. of New Gd+
`Mean No. of New Gd+ Lesions Per
`
`Lesions Per Scan
`Scan/ Mean No. Baseline Gd+ Lesions
`
`
`0 Lesions on
`Baseline Exam
`
`1 Lesions on
`Baseline Exam
`
`2 Lesions on
`Baseline Exam
`
`3 Lesions on
`Baseline Exam
`
`i
`
`1.9
`
`19
`
`3.1
`
`
`
`Page1 of 1
`
`1/0 = Undefined
`
`1.9/1 = 1,9
`
`1.9/2 = 0.95
`
`5.1/3 = 1.7
`
`
`
`
`
`
`
`
`
`: y aR21 6 -Ol4O7 Q
`Biogen Exhibit 2220 [2 _2220 §
`Mylanv. Biogen
`IPR 2018-01403
`
`
`
`Page 1 of 1
`
`Biogen Exhibit 2220
`Mylan v. Biogen
`IPR 2018-01403
`
`